119 related articles for article (PubMed ID: 33341987)
1. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
Singh HM; Bailey P; Hübschmann D; Berger AK; Neoptolemos JP; Jäger D; Siveke J; Springfeld C
Genes Chromosomes Cancer; 2021 May; 60(5):373-384. PubMed ID: 33341987
[TBL] [Abstract][Full Text] [Related]
2. Emerging strategies in BRCA-positive pancreatic cancer.
Kowalewski A; Szylberg Ł; Saganek M; Napiontek W; Antosik P; Grzanka D
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1503-1507. PubMed ID: 29777302
[TBL] [Abstract][Full Text] [Related]
3. Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer.
LaRose M; Manji GA; Bates SE
Semin Oncol; 2024; 51(1-2):36-44. PubMed ID: 38171988
[TBL] [Abstract][Full Text] [Related]
4. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Pishvaian MJ; Biankin AV; Bailey P; Chang DK; Laheru D; Wolfgang CL; Brody JR
Br J Cancer; 2017 Apr; 116(8):1021-1026. PubMed ID: 28291774
[TBL] [Abstract][Full Text] [Related]
5. Molecular characteristics of
Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
[TBL] [Abstract][Full Text] [Related]
6. Next-generation therapies for pancreatic cancer.
Buckley CW; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2024; 18(1-3):55-72. PubMed ID: 38415709
[TBL] [Abstract][Full Text] [Related]
7. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
8. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma.
Cleary JM; Wolpin BM; Dougan SK; Raghavan S; Singh H; Huffman B; Sethi NS; Nowak JA; Shapiro GI; Aguirre AJ; D'Andrea AD
Clin Cancer Res; 2021 Dec; 27(24):6622-6637. PubMed ID: 34285063
[TBL] [Abstract][Full Text] [Related]
9. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.
Perkhofer L; Gout J; Roger E; Kude de Almeida F; Baptista Simões C; Wiesmüller L; Seufferlein T; Kleger A
Gut; 2021 Mar; 70(3):606-617. PubMed ID: 32855305
[TBL] [Abstract][Full Text] [Related]
10. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
Singh RR; O'Reilly EM
Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy.
Geerinckx B; Teuwen LA; Foo T; Vandamme T; Smith A; Peeters M; Price T
Expert Rev Anticancer Ther; 2023; 23(12):1237-1249. PubMed ID: 37842857
[TBL] [Abstract][Full Text] [Related]
12. Advances in Systemic Therapy in Pancreatic Cancer.
Yu KH
Hematol Oncol Clin North Am; 2024 Jun; 38(3):617-627. PubMed ID: 38575456
[TBL] [Abstract][Full Text] [Related]
13. A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.
Alruwaili MM; Zonneville J; Naranjo MN; Serio H; Melendy T; Straubinger RM; Gillard B; Foster BA; Rajan P; Attwood K; Chatley S; Iyer R; Fountzilas C; Bakin AV
Cell Rep Med; 2024 Mar; 5(3):101434. PubMed ID: 38387463
[TBL] [Abstract][Full Text] [Related]
14. Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?
Teo MY; O'Reilly EM
J Gastrointest Oncol; 2016 Oct; 7(5):738-749. PubMed ID: 27747088
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients.
Freed IM; Kasi A; Fateru O; Hu M; Gonzalez P; Weatherington N; Pathak H; Hyter S; Sun W; Al-Rajabi R; Baranda J; Hupert ML; Chalise P; Godwin AK; A Witek M; Soper SA
Cells; 2023 Sep; 12(18):. PubMed ID: 37759489
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations in pancreatic cancer and potential new therapeutic options.
Pihlak R; Valle JW; McNamara MG
Oncotarget; 2017 Sep; 8(42):73240-73257. PubMed ID: 29069866
[TBL] [Abstract][Full Text] [Related]
17. Treatment Options for Germline
Grzelak D
J Adv Pract Oncol; 2021 Jul; 12(5):488-491. PubMed ID: 34430059
[TBL] [Abstract][Full Text] [Related]
18. Germline Variants in DNA Damage Repair Genes: An Emerging Role in the Era of Precision Medicine in Pancreatic Adenocarcinoma.
Shoucair S; Baker AR; Yu J
Ann Gastroenterol Surg; 2022 Jan; 6(1):7-16. PubMed ID: 35106410
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer.
Saha A; Zhao S; Chen Z; Georgiou G; Stone E; Kidane D; DiGiovanni J
Mol Ther; 2021 Feb; 29(2):775-787. PubMed ID: 33091613
[TBL] [Abstract][Full Text] [Related]
20. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
Kasi A; Al-Jumayli M; Park R; Baranda J; Sun W
J Pancreat Cancer; 2020; 6(1):107-115. PubMed ID: 33376937
[No Abstract] [Full Text] [Related]
[Next] [New Search]
